There was clinically significant less CME in patients who received trans-zonular triamcinolone acetonide, moxifloxacin hydrochloride, and vancomycin—known as the Dropless approach—in addition to an NSAID after cataract surgery.
A hot topic in cataract surgery is alternative ways to administer perioperative medications with the goal of lowering the incidence of cystoid macular edema (CME). One way to achieve that goal would be the combination of non-steroidal anti-inflammatory drugs (NSAIDs) and transzonular steroids.
Postoperative patients with PXF pose both short- and long-term concerns due to the underlying pathological changes that occur from the fibrillar deposition with some complications arising years after the surgery.
As the final common pathway in many retinal disorders, macular edema can be considered the leading cause of visual loss in the developed world, and thus has an enormous socioeconomic importance, according to Mark Johnson, MD.
A retrospective analysis including data from a consecutive series of 1575 eyes shows that intravitreal placement of triamcinolone/moxifloxacin during cataract surgery is a safe and effective method for preventing inflammation, endophthalmitis, and cystoid macular edema.